AKER BIOMARINE 28 April 2023 :Aker BioMarine ASA ("Aker BioMarine " or "the company") reports revenues ofUSD 69 million and Adjusted EBITDA ofUSD 6.0 million for the first quarter 2023. Highlights first quarter: - Revenues ofUSD 69.0 , up 22% year over year - Adjusted EBITDA ofUSD 6.0 million , down fromUSD 8.1 million last year - Krill offshore production stable YoY at 19,852 MT (20,809 MT) - Revenues in the Ingredients segment ofUSD 41.6 million , up 38% YoY - Revenues in the Brands segment ofUSD 33.5 million , up 10% YoY - Event after the quarter end: Final approval for the Superba health claim in the South Korean market- preparing for re-launch in second quarter. "Aker BioMarine delivers sales growth in all segments compared to the same quarter last year. Our krill oil product Superba continued the positive sales trend, driven by good development inAsia ,Europe and US mass market. On back of this it is exciting to announce the approval for Superba as Health Functional Food in the South Korean market, and we will now re-launch marketing and sales together with our long-term local partner. Our harvesting fleet are performing well, and we are tracking on par with the strong beginning of last year.", saidMatts Johansen , CEO ofAker BioMarine . Outlook For second quarter 2023 we expect Qrill Aqua and Superba revenues, as well as Brands revenues to be above same quarter last year. We also expect Superba sales in second quarter to be on par or above with first quarter 2023. We expect long-term average annual sales growth forAker BioMarine to be in line with earlier communicated ambitions at around 15%. At09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com. The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor. A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address. For further information, please contactKatrine Klaveness , CFO Mobile: +47 991 58 915 Email: Katrine.Klaveness@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source
